Farmas USA

ACHN

Yo las ACHN las estoy mirando para corto, pero aún no... El conjunto de gráficos me dice que quiere superar la banda superior de las bolinger.

ACHN, menos mal que no te has tirado al corto. Lleva un +17%

si vas a hacer algun corto aqui, supongo que será intradía. Yo veo ACHN hacia arriba en el medio plazo. No digo que se vayan a duplicar pero apreciación sobre los precios de ahora, si.

Achn

Soltadas a 3,42

Offtopic

Casi no he podido seguir la sesión, pero veo que me he librado por los pelos de otro castañazo. Vendidas a 5.50, desde 5.20

https://www.cnbc.com/2018/02/26/fitbit-earnings-q4-2017.html

FIT

Amarin (NASDAQ:AMRN): Q4 EPS of -$0.08 misses by $0.04.
Revenue of $53.9M (+39.3% Y/Y) beats by $3.3M

Analysis of top Seeking Alpha coverage: Progenics

https://seekingalpha.com/article/4150823-daily-pharma-scoop-progenics-update-la-jolla-data-arca-biopharma-setback

Today we will discuss Progenics Pharmaceuticals ( PGNX), which last week  presented at the RBC Capital Markets Global Healthcare Conference.

As we have  noted before, Progenics has an important upcoming catalyst, which could provide a significant boost to the stock price. On April 30th, the FDA will decide on the New Drug Application (NDA) for Progenics’ Azedra. The NDA submission is based on data from the phase 2b study, which was partially conducted by Progenics. The study was initiated by Molecular Insights under a Special Protocol Assessment (( SPA)) from the FDA. But Molecular Insights fell into cash problems and had to forfeit the study. Progenics picked up from where Molecular Insights left.

While the phase 2b efficacy data in the PGNX portion of the trial has been poorer when compared to what Molecular Insights reported from its portion of the trial, the overall trial results meet the SPA requirement. We continue to believe that because the study met the requirement under the SPA, Azedra is likely to get an approval on April 30th.

Azedra is the near-term commercial opportunity for PGNX. Longer-term, the value driver is going to be the company’s PSMA-targeted portfolio for prostate cancer, especially 1404.

PGNX

TEVA como le dé por iniciar bajada continuada , a esta no la para ni Warren Buffet,....ni mucho menos Paramés....Cierto que manejan cantidades enormes de capital , pero dudo de si conocen cómo se las gastan estas bichas ..., creo que cobran por su conocimiento, .🤔, en este foro creo que no cobra nadie ....🙄